StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.48−0.05 (-0.66%)

Close on Nov 18, 2026Market cap $3.39BP/E –Yield –

Iovance Biotherapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Iovance Biotherapeutics's price to book ratio was 5.0× on Nov 11, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 0.7× to 9.1×, with a median of 2.7×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20265.0×+3.5
2025Dec 31, 20251.5×−1.4
2024Dec 31, 20242.9×−0.2
2023Dec 29, 20233.1×+0.5
2022Dec 30, 20222.6×−1.7
2021Dec 31, 20214.3×−5.3
2020Dec 31, 20209.6×−0.3
2019Dec 31, 20199.8×+6.4
2018Dec 31, 20183.4×−0.1
2017Dec 29, 20173.5×+1.1
2016Dec 30, 20162.4×−1.0
2015Dec 31, 20153.4×−10.1
2014Dec 31, 201413.5×−148.1
2011Jul 29, 2011161.6×–

More Iovance Biotherapeutics figures

See a number that looks wrong?